Sunday, September 13, 2026

TWS Achieves Platinum Status in Japan: How “SODA SODA” Became a Sensation

TWS proves global popularity by receiving additional Gold Disc certification from the Japan Record Association.

U.S. and South Korea Strengthen Alliance Amid North Korea’s Nuclear Threats

South Korean Defense Minister Kim Yong Hyun held his first cooperative phone call with U.S. Defense Secretary Lloyd Austin.

JW Life Science launches medical care brand “Dr. Claro”

JW Life Science launches "Dr. Claro," a medical care brand with five certified products for wound management and skin protection.

Tag: Celltrion

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

Celtrion’s Steqeyma Seizes 16% Market Share in the U.S.: What’s Next for This Autoimmune Treatment?

Celltrion's autoimmune drug Steqeyma surpasses 16% market share in the U.S., accelerating prescription growth and expansion.

“Second-Half Performance to Outpace First Half”… Celltrion Expected to Exceed Full-Year Revenue Target

Celltrion is expected to outperform its first-half results in the second half, driven by new-product growth, European tender wins and stronger demand for high-margin products, potentially allowing it to exceed its full-year targets.

Unlocking the Future: Why 340,000 Families Trust Celltrion’s Cord Blood Banking in 2026

Medipost announces that its brand, Celltrion, has surpassed 340,000 cord blood storage units in South Korea.

Celltrion’s CT-P51: Will This Keytruda Biosimilar Disrupt the 44 Billion USD Cancer Drug Market?

Celltrion has applied for approval of its biosimilar CT-P51 for the global blockbuster immuno-oncology drug Keytruda (pembrolizumab).

Celltrion Completes Integration of France’s Gifrer, Targets European Pharmacy Network

Celltrion has completed the post-acquisition integration of French health care company Gifrer and plans to use its pharmacy network as a hub for expanding direct sales across Europe.

Celltrion Publishes Population Pharmacokinetic Analysis of Vegzelma in International Journal

Celltrion has published integrated population pharmacokinetic analysis results for its Avastin biosimilar Vegzelma, confirming pharmacokinetic similarity with the reference drug.

Celltrion’s Three ADC Drug Candidates All Receive FDA Fast Track Designation

Celltrion has secured U.S. FDA Fast Track designation for all three of its antibody-drug conjugate candidates, accelerating development of its emerging oncology drug pipeline.

Celltrion Expands Market Presence With Major Tender Wins in Spain and Portugal

Celltrion is accelerating its expansion in Spain and Portugal through major tender wins, rising prescriptions and a strengthened direct-sales strategy across its biosimilar portfolio.

Celltrion accelerates mechanism diversification strategy, expands autoimmune disease portfolio

Celltrion accelerates the development of biosimilars for autoimmune disease treatments, expanding its portfolio for long-term growth.

Celltrion expands U.S. PBM coverage, boosting outlook for high-margin biosimilars

Celltrion expands its listing with US PBM, enhancing its high-profit biosimilar product base and boosting sales expectations for H2.

Celltrion’s Omlyclo Gains Traction in Italy, Reinforcing Direct Sales Strategy as Growth Expected to Accelerate

Celltrion expands its biosimilar supply in Italy, enhancing its competitiveness in the European pharmaceutical market.

Celltrion Files for European Approval of Cosentyx Biosimilar, Targets $6.7 Billion Market

Celltrion has filed for European approval of its CT-P55 biosimilar for autoimmune diseases, aiming for early market entry and expansion.

Celltrion Group’s 2 Trillion KRW Investment: What It Means for Global Bio Manufacturing by 2032

Celltrion Group plans a 2 trillion KRW investment to enhance production capacity and establish a leading position in global biotech.

Celltrion Expands PFS Production Capacity to 70 Million: What This Means for the Global Market

Celltrion Pharmaceutical plans to invest 2 trillion KRW to expand its pre-filled syringe production capacity to meet global demand.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.